Effects of high affinity leptin antagonist on prolactin receptor deficient male mouse

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Carré, Nadège ^a,b   Solomon, Gili ^c   Gertler, Arieh ^c   Binart, Nadine ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; HORMONE ANTAGONIST; INSULIN; LEPTIN; LIPID; PEGYLATED SUPERACTIVE MOUSE LEPTIN ANTAGONIST; PROLACTIN RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; PEGYLATED LEPTIN;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BONE MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCOSE INTOLERANCE; HORMONE ACTION; HYPERPROLACTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; GLUCOSE TOLERANCE TEST; KNOCKOUT MOUSE; OBESITY; PHYSIOLOGY; TRABECULAR MESHWORK; WEIGHT GAIN;

ADIPOSITY; ANIMALS; BONE AND BONES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, KNOCKOUT; POLYETHYLENE GLYCOLS; RECEPTORS, PROLACTIN; TRABECULAR MESHWORK; WEIGHT GAIN;

EID: 84899801928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091422     Document Type: Article

References (20)

1. Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin: the new biology of an old hormone. Annu Rev Physiol 64: 47-67. doi:10.1146/annurev. physiol. 64.081501.131049.
2. Ben-Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocr Rev 29: 1-41. doi:10.1210/er.2007- 0017. (Pubitemid 351252745)
3. Sauvé D, Woodside B (2000) Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res 868: 306-314. (Pubitemid 30347527)
4. Chen P, Smith MS (2004) Regulation of hypothalamic neuropeptide Y messenger ribonucleic acid expression during lactation: role of prolactin. Endocrinology 145: 823-829. doi:10.1210/en.2003-1255. (Pubitemid 38183826)
5. Ling C, Hellgren G, Gebre-Medhin M, Dillner K, Wennbo H, et al. (2000) Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice. Endocrinology 141: 3564-3572.
6. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51: 242-246. (Pubitemid 10007626)
7. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48: 547-553. (Pubitemid 28252990)
8. Naliato ECO, Violante AHD, Caldas D, Lamounier Filho A, Loureiro CR, et al. (2007) Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf) 67: 845-852. doi:10.1111/j.1365-2265.2007.02973. x. (Pubitemid 350135126)
9. Meyre D, Delplanque J, Chèvre J-C, Lecoeur C, Lobbens S, et al. (2009) Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 41: 157-159. doi:10.1038/ng.301.
10. Nilsson L, Olsson AH, Isomaa B, Groop L, Billig H, et al. (2011) A common variant near the PRL gene is associated with increased adiposity in males. Mol Genet Metab 102: 78-81. doi:10.1016/j.ymgme.2010.08.017.
11. Auffret J, Viengchareun S, Carré N, Denis RGP, Magnan C, et al. (2012) Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J Off Publ Fed Am Soc Exp Biol 26: 3728-3737. doi:10.1096/fj.12-204958.
12. Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, et al. (2011) Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem 286: 4429-4442. doi:10.1074/jbc.M110.196402.
13. Chapnik N, Solomon G, Genzer Y, Miskin R, Gertler A, et al. (2013) A superactive leptin antagonist alters metabolism and locomotion in high-leptin mice. J Endocrinol 217: 283-290. doi:10.1530/JOE-13-0033.
14. Viengchareun S, Servel N, Fève B, Freemark M, Lombès M, et al. (2008) Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2. PloS One 3: e1535. doi:10.1371/journal.pone.0001535.
15. Freemark M, Fleenor D, Driscoll P, Binart N, Kelly P (2001) Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 142: 532-537. (Pubitemid 32222400)
16. Solomon G, Atkins A, Shahar R, Gertler A, Monsonego-Ornan E (2013) Effect of peripherally administered leptin antagonist on whole-body metabolism, and bone microarchitecture and biomechanical properties in mouse. Am J Physiol Endocrinol Metab. doi:10.1152/ajpendo.00155.2013.
17. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab TEM 17: 110-116. doi:10.1016/j.tem.2006.02.005.
18. Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, et al. (2005) Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J Endocrinol 187: 45-53. doi:10.1677/joe.1.06333. (Pubitemid 41556400)
19. Syberg S, Schwarz P, Petersen S, Steinberg TH, Jensen J-EB, et al. (2012) Association between P2X7 Receptor Polymorphisms and Bone Status in Mice. J Osteoporos 2012: 637986. doi:10.1155/2012/637986.
20. Elinav E, Niv-Spector L, Katz M, Price TO, Ali M, et al. (2009) Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 150: 3083-3091. doi:10.1210/en.2008-1706.